Wu Xiaoqiu, Shaikh Atik Badshah, Yu Yuanyuan, Li Yongshu, Ni Shuaijian, Lu Aiping, Zhang Ge
Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University (HKBU), Hong Kong 999077, China.
Int J Mol Sci. 2017 Aug 25;18(9):1851. doi: 10.3390/ijms18091851.
Breast cancer is one of the most common causes of cancer related deaths in women. Currently, with the development of early detection, increased social awareness and kinds of treatment options, survival rate has improved in nearly every type of breast cancer patients. However, about one third patients still have increased chances of recurrence within five years and the five-year relative survival rate in patients with metastasis is less than 30%. Breast cancer contains multiple subtypes. Each subtype could cause distinct clinical outcomes and systemic interventions. Thereby, new targeted therapies are of particular importance to solve this major clinical problem. Aptamers, often termed "chemical antibodies", are functionally similar to antibodies and have demonstrated their superiority of recognizing target with high selectivity, affinity and stability. With these intrinsic properties, aptamers have been widely studied in cancer biology and some are in clinical trials. In this review, we will firstly discuss about the global impacts and mechanisms of breast cancer, then briefly highlight applications of aptamers that have been developed for breast cancer and finally summarize various challenges in clinical translation of aptamers.
乳腺癌是女性癌症相关死亡的最常见原因之一。目前,随着早期检测技术的发展、社会意识的提高以及多种治疗选择,几乎每种类型的乳腺癌患者的生存率都有所提高。然而,约三分之一的患者在五年内仍有较高的复发几率,而发生转移的患者的五年相对生存率低于30%。乳腺癌包含多种亚型。每种亚型都可能导致不同的临床结果和全身干预措施。因此,新的靶向治疗对于解决这一重大临床问题尤为重要。适体,常被称为“化学抗体”,在功能上与抗体相似,并已证明其在高选择性、亲和力和稳定性方面识别靶点的优势。凭借这些内在特性,适体已在癌症生物学中得到广泛研究,有些正处于临床试验阶段。在本综述中,我们将首先讨论乳腺癌的全球影响和机制,然后简要介绍已开发用于乳腺癌的适体的应用,最后总结适体临床转化中的各种挑战。